[{"id":"8f37731b-089c-47c1-a812-0b453cccb247","acronym":"DENIVOS","url":"https://clinicaltrials.gov/study/NCT03669523","created_at":"2021-01-18T18:00:15.676Z","updated_at":"2025-02-25T15:10:56.744Z","phase":"Phase 2","brief_title":"Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)","source_id_and_acronym":"NCT03669523 - DENIVOS","lead_sponsor":"Centre Hospitalier Annecy Genevois","biomarkers":" EGFR • PD-L1 • BRAF • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 10/19/2023","primary_completion_date":" 10/19/2023","study_txt":" Completion: 10/19/2023","study_completion_date":" 10/19/2023","last_update_posted":"2025-02-13"},{"id":"59dec683-38a1-466b-9e1a-d449d5594e00","acronym":"BRCA-P","url":"https://clinicaltrials.gov/study/NCT04711109","created_at":"2021-01-19T20:52:27.605Z","updated_at":"2024-07-02T16:35:01.267Z","phase":"Phase 3","brief_title":"Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation","source_id_and_acronym":"NCT04711109 - BRCA-P","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/14/2023","start_date":" 02/14/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2024-05-23"},{"id":"03b45cf1-cf37-418b-9569-62effa70b0e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620019","created_at":"2021-02-22T18:20:21.125Z","updated_at":"2024-07-02T16:35:09.864Z","phase":"Phase 2","brief_title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","source_id_and_acronym":"NCT03620019","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Prolia (denosumab)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 09/25/2018","start_date":" 09/25/2018","primary_txt":" Primary completion: 04/15/2023","primary_completion_date":" 04/15/2023","study_txt":" Completion: 08/15/2023","study_completion_date":" 08/15/2023","last_update_posted":"2024-04-12"},{"id":"9859e970-9a54-49ce-a778-b43380a497a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05590949","created_at":"2022-10-21T13:56:06.929Z","updated_at":"2024-07-02T16:35:24.995Z","phase":"","brief_title":"Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors","source_id_and_acronym":"NCT05590949","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/18/2022","start_date":" 10/18/2022","primary_txt":" Primary completion: 10/18/2024","primary_completion_date":" 10/18/2024","study_txt":" Completion: 10/18/2024","study_completion_date":" 10/18/2024","last_update_posted":"2023-12-28"},{"id":"33ac04c5-2120-44f3-8b09-e7a67691ecd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03324932","created_at":"2021-01-18T16:25:08.420Z","updated_at":"2024-07-02T16:35:34.312Z","phase":"Phase 3","brief_title":"Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer","source_id_and_acronym":"NCT03324932","lead_sponsor":"Kyoto Prefectural University of Medicine","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 09/25/2017","start_date":" 09/25/2017","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-10-06"},{"id":"2697ccff-3b70-4de9-a777-812b3d98f80b","acronym":"ABCSG-18","url":"https://clinicaltrials.gov/study/NCT00556374","created_at":"2021-01-18T02:01:40.862Z","updated_at":"2024-07-02T16:35:41.885Z","phase":"Phase 3","brief_title":"Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","source_id_and_acronym":"NCT00556374 - ABCSG-18","lead_sponsor":"Amgen","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 3420","initiation":"Initiation: 12/18/2006","start_date":" 12/18/2006","primary_txt":" Primary completion: 10/07/2014","primary_completion_date":" 10/07/2014","study_txt":" Completion: 07/26/2022","study_completion_date":" 07/26/2022","last_update_posted":"2023-07-27"},{"id":"7b0ba66c-2631-4f1a-8968-6a382b6a6cdd","acronym":"D-BIOMARK","url":"https://clinicaltrials.gov/study/NCT03691311","created_at":"2021-01-18T18:05:34.006Z","updated_at":"2024-07-02T16:36:21.535Z","phase":"Phase 1","brief_title":"Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer","source_id_and_acronym":"NCT03691311 - D-BIOMARK","lead_sponsor":"Institut Català d'Oncologia","biomarkers":" HER-2 • ER • CASP3 • TNFSF11","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • CASP3 • TNFSF11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/05/2018","start_date":" 07/05/2018","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 02/05/2023","study_completion_date":" 02/05/2023","last_update_posted":"2021-11-03"},{"id":"88a55a61-38e3-4292-be29-cd8c332d6d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT01951586","created_at":"2021-10-25T18:54:29.396Z","updated_at":"2024-07-02T16:36:22.500Z","phase":"Phase 2","brief_title":"Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01951586","lead_sponsor":"Amgen","biomarkers":" TNFRSF11A • TNFSF11","pipe":"","alterations":" ","tags":["TNFRSF11A • TNFSF11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 226","initiation":"Initiation: 12/31/2013","start_date":" 12/31/2013","primary_txt":" Primary completion: 07/29/2016","primary_completion_date":" 07/29/2016","study_txt":" Completion: 11/28/2017","study_completion_date":" 11/28/2017","last_update_posted":"2021-10-25"},{"id":"329996b5-121a-4160-83d8-620215815878","acronym":"GeparX","url":"https://clinicaltrials.gov/study/NCT02682693","created_at":"2021-01-18T13:04:55.606Z","updated_at":"2025-02-25T14:00:55.583Z","phase":"Phase 2","brief_title":"Denosumab as an add-on Neoadjuvant Treatment (GeparX)","source_id_and_acronym":"NCT02682693 - GeparX","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • ER • PGR • TNFRSF11A","pipe":" | ","alterations":" HER-2 positive • ER negative","tags":["HER-2 • ER • PGR • TNFRSF11A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Prolia (denosumab) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 780","initiation":"Initiation: 02/13/2017","start_date":" 02/13/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2021-02-02"},{"id":"11bb4cea-1e1a-4e56-9a66-9e579c9ebaa8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02900469","created_at":"2022-02-23T21:53:07.158Z","updated_at":"2024-07-02T16:36:41.781Z","phase":"Phase 1","brief_title":"Presurgical Trial of Denosumab in Breast Cancer","source_id_and_acronym":"NCT02900469","lead_sponsor":"NYU Langone Health","biomarkers":" TNFSF11","pipe":"","alterations":" ","tags":["TNFSF11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/03/2019","primary_completion_date":" 12/03/2019","study_txt":" Completion: 01/03/2020","study_completion_date":" 01/03/2020","last_update_posted":"2020-08-21"},{"id":"2bddecae-a53c-4f25-8868-153d61b946fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03629717","created_at":"2021-04-26T09:52:58.772Z","updated_at":"2024-07-02T16:36:46.012Z","phase":"Phase 1","brief_title":"RANKL Inhibition and Breast Tissue Biomarkers","source_id_and_acronym":"NCT03629717","lead_sponsor":"Washington University School of Medicine","biomarkers":" TNFRSF11A","pipe":"","alterations":" ","tags":["TNFRSF11A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 12/03/2018","primary_completion_date":" 12/03/2018","study_txt":" Completion: 12/03/2018","study_completion_date":" 12/03/2018","last_update_posted":"2020-04-14"},{"id":"49d7a14a-2cfd-4c55-ad9f-f1d91952bcf4","acronym":"PERIDENO","url":"https://clinicaltrials.gov/study/NCT03532087","created_at":"2021-01-18T17:23:57.293Z","updated_at":"2024-07-02T16:36:51.252Z","phase":"Phase 2","brief_title":"Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03532087 - PERIDENO","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2 • IFNG • TNFA • CD4 • TNFSF11","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • IFNG • TNFA • CD4 • TNFSF11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2020-01-18"},{"id":"83457aae-a1ca-404f-b151-9dfae99c568a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02274623","created_at":"2022-01-21T19:53:41.049Z","updated_at":"2024-07-02T16:36:55.111Z","phase":"Phase 1","brief_title":"Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid","source_id_and_acronym":"NCT02274623","lead_sponsor":"OPKO Health, Inc.","biomarkers":" TAP1","pipe":"","alterations":" ","tags":["TAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 02/27/2017","primary_completion_date":" 02/27/2017","study_txt":" Completion: 03/17/2017","study_completion_date":" 03/17/2017","last_update_posted":"2019-09-27"},{"id":"776eb7f9-adf5-46d4-8cef-d2bc4c10c7d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03605199","created_at":"2023-06-15T16:08:15.111Z","updated_at":"2024-07-02T16:36:56.577Z","phase":"Phase 2","brief_title":"Denosumab in Subjects With Giant Cell Rich Tumors of Bone","source_id_and_acronym":"NCT03605199","lead_sponsor":"Leiden University Medical Center","biomarkers":" GCG","pipe":"","alterations":" ","tags":["GCG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/18/2018","start_date":" 06/18/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2019-08-26"},{"id":"f9998ea4-ca9a-48d5-92ac-38447f1f517d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03811509","created_at":"2021-01-18T18:50:02.946Z","updated_at":"2024-07-02T16:37:03.445Z","phase":"Phase 4","brief_title":"Breast Cancer Women on Aromatase Inhibitors Treatment","source_id_and_acronym":"NCT03811509","lead_sponsor":"Parc de Salut Mar","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Prolia (denosumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-01-28"},{"id":"608db89e-4191-4974-9489-bc467456a69a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00089661","created_at":"2021-01-18T00:16:13.112Z","updated_at":"2024-07-02T16:37:06.017Z","phase":"Phase 3","brief_title":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer","source_id_and_acronym":"NCT00089661","lead_sponsor":"Amgen","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Completed","enrollment":" Enrollment 252","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 05/11/2007","primary_completion_date":" 05/11/2007","study_txt":" Completion: 05/27/2009","study_completion_date":" 05/27/2009","last_update_posted":"2018-10-17"},{"id":"d0720c37-2a12-40d4-ad50-cde72e0d168e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03259152","created_at":"2021-01-18T16:06:04.187Z","updated_at":"2024-07-02T16:37:18.509Z","phase":"Phase 3","brief_title":"Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone","source_id_and_acronym":"NCT03259152","lead_sponsor":"Hebei Medical University Third Hospital","biomarkers":" KEAP1 • COL1A1 • GAPDH • ACAN • TNFRSF11B","pipe":"","alterations":" ","tags":["KEAP1 • COL1A1 • GAPDH • ACAN • TNFRSF11B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2017-08-24"}]